Allos Therapeutics (ALTH) Reports Q2 Profit of 2c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts ALTH Hot Sheet
Price: $1.84 --0%
Financial Fact:
Cost of sales, excluding amortization expense: 941K
Today's EPS Names:
AEHR, VFS, CMTL, More
Financial Fact:
Cost of sales, excluding amortization expense: 941K
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Allos Therapeutics (NASDAQ: ALTH) reported Q2 EPS of $0.02, $0.16 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.91 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Althea Copper acquires 100% of Manitoba copper-zinc property
- Neogen Corp. (NEOG) Tops Q1 EPS by 3c
- Constellation Brands (STZ) Beats Q2 EPS by 13c, Revenue Beats, Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
